Gastroesophageal Reflux Disease (GERD) and Non-Erosive Reflux Disease (NERD) treatments encompass pharmaceuticals like proton pump inhibitors (PPIs, 75-80% of the market) and H2 receptor blockers to manage acid reflux symptoms. The market is driven by hospitals and clinics (50-60%) and drugstores (40-45%), with PPIs like Haleon’s and AstraZeneca’s leading due to efficacy.
Haleon, formed in 2022 from GSK’s consumer health unit, focuses on over-the-counter solutions. The industry is moderately concentrated, with Takeda and AstraZeneca leading prescription drugs. Innovations target long-acting PPIs and non-drug therapies. Challenges include generic competition, side effect concerns, and regulatory scrutiny, yet rising GERD prevalence drives growth.
This product will be delivered within 1-3 business days.
Haleon, formed in 2022 from GSK’s consumer health unit, focuses on over-the-counter solutions. The industry is moderately concentrated, with Takeda and AstraZeneca leading prescription drugs. Innovations target long-acting PPIs and non-drug therapies. Challenges include generic competition, side effect concerns, and regulatory scrutiny, yet rising GERD prevalence drives growth.
Market Size and Growth Forecast
The global GERD & NERD Treatment market is projected to reach USD 7.5-8.5 billion by 2025, with an estimated compound annual growth rate (CAGR) of 2% to 3% through 2030. Growth is driven by aging populations and lifestyle-related GERD cases.Regional Analysis
- North America holds 35-40%, with a growth rate of 2%-3%. The U.S. leads in hospital treatments, with Canada focusing on drugstores. Trends include OTC adoption.
- Asia Pacific accounts for 25-30%, with a growth rate of 3%-4%. Japan’s Eisai and India’s Dr. Reddy’s drive drugstore sales. Trends focus on generics.
- Europe holds 30-35%, with a growth rate of 2%-3%. Germany’s STADA focuses on PPIs. Trends include non-drug therapies.
- Middle East and Africa hold 2-3%, with a growth rate of 1%-2%. The UAE’s hospitals grow, but access lags. Trends include affordability.
- South America accounts for 1-2%, with a growth rate of 1%-2%. Brazil’s drugstores support demand. Trends focus on generics.
Application Analysis
- Hospitals & Clinics: Holds 50-60%, with a growth rate of 2%-3%. Takeda’s PPIs dominate hospital prescriptions. Trends include combination therapies.
- Drugstore: Accounts for 40-45%, with a growth rate of 2.5%-3.5%. Haleon’s OTC solutions lead. Trends focus on self-medication.
- Research Centers: Holds 0-1%, with a growth rate of 1%-2%. AbbVie’s trials grow. Trends include novel drugs.
- Others: Accounts for 0-1%, with a growth rate of 1%-2%. Niche therapies grow with Sandoz’s offerings.
Type Analysis
- Proton Pump Inhibitors: Holds 75-80%, with a growth rate of 2%-3%. AstraZeneca’s PPIs lead. Trends include long-acting formulations.
- H2 Receptor Blocker: Accounts for 5-10%, with a growth rate of 1%-2%. Teva’s blockers grow. Trends focus on affordability.
- Petroleum Cracking Method (Antacids): Holds 10-15%, with a growth rate of 1.5%-2.5%. Haleon’s antacids lead. Trends include fast-acting solutions.
- Others: Accounts for 1-3%, with a growth rate of 1%-2%. Novel therapies grow with Eisai’s offerings.
Key Market Players
- Takeda Pharmaceutical: A Japanese firm, Takeda develops PPIs for hospitals.
- AstraZeneca: A UK company, AstraZeneca focuses on PPIs for clinics.
- Haleon: A UK firm, Haleon supplies OTC antacids.
- Teva Pharmaceutical: An Israeli company, Teva develops H2 blockers.
- Eisai: A Japanese firm, Eisai focuses on novel therapies.
- Aurobindo Pharma: An Indian company, Aurobindo supplies generics.
- Dr. Reddy’s Laboratories: An Indian firm, Dr. Reddy’s develops PPIs.
- STADA: A German company, STADA focuses on OTC PPIs.
- AbbVie: A U.S. firm, AbbVie supplies hospital therapies.
- Johnson & Johnson: A U.S. company, Johnson & Johnson develops antacids.
- Sandoz: A Swiss firm, Sandoz focuses on generics.
- Viatris: A U.S. company, Viatris supplies H2 blockers.
Porter’s Five Forces Analysis
- Threat of New Entrants: Low. Regulatory barriers deter entry, with AstraZeneca dominating.
- Threat of Substitutes: Moderate. Non-drug therapies compete, but Takeda’s PPIs retain efficacy.
- Bargaining Power of Buyers: High. Pharmacies switch suppliers, pressuring Haleon for pricing.
- Bargaining Power of Suppliers: Low. API suppliers have limited influence, with Teva’s scale reducing dependency.
- Competitive Rivalry: High. AstraZeneca and Takeda compete on efficacy and pricing.
Market Opportunities and Challenges
Opportunities
- Aging Population: GERD prevalence boosts Takeda’s sales.
- OTC Growth: Self-medication drives Haleon’s expansion.
- Generic Expansion: India’s demand favors Dr. Reddy’s growth.
- Emerging Markets: Brazil’s drugstores support Aurobindo’s share.
- Novel Therapies: Non-drug solutions boost Eisai’s adoption.
- Hospital Demand: Combination therapies favor AbbVie’s growth.
- Lifestyle Trends: Dietary habits enhance STADA’s revenue.
Challenges
- Generic Competition: Low-cost drugs pressure AstraZeneca’s margins.
- Side Effect Concerns: PPI risks affect Takeda’s adoption.
- Regulatory Scrutiny: Approvals slow Haleon’s innovation.
- Market Saturation: Mature markets challenge Dr. Reddy’s expansion.
- Supply Chain Issues: API delays disrupt Aurobindo’s delivery.
- Non-Drug Therapies: Lifestyle changes threaten Eisai’s share.
- Pricing Pressures: Reimbursement cuts affect STADA’s profitability.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
Chapter 4 Market Landscape
Chapter 5 Market Trend Analysis
Chapter 6 Industry Chain Analysis
Chapter 7 Latest Market Dynamics
Chapter 8 Historical and Forecast Gerd & Nerd Treatment Market in North America (2020-2030)
Chapter 9 Historical and Forecast Gerd & Nerd Treatment Market in South America (2020-2030)
Chapter 10 Historical and Forecast Gerd & Nerd Treatment Market in Asia & Pacific (2020-2030)
Chapter 11 Historical and Forecast Gerd & Nerd Treatment Market in Europe (2020-2030)
Chapter 12 Historical and Forecast Gerd & Nerd Treatment Market in MEA (2020-2030)
Chapter 13 Summary For Global Gerd & Nerd Treatment Market (2020-2025)
Chapter 14 Global Gerd & Nerd Treatment Market Forecast (2025-2030)
Chapter 15 Analysis of Global Key Vendors
List of Tables and Figures
Companies Mentioned
- Takeda Pharmaceutical
- AstraZeneca
- Haleon
- Teva Pharmaceutical
- Eisai
- Aurobindo Pharma
- Dr. Reddy's Laboratories
- STADA
- AbbVie
- Johnson & Johnson
- Sandoz
- Viatris
